These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19043742)

  • 21. Stability of an extemporaneously compounded levothyroxine sodium oral liquid.
    Boulton DW; Fawcett JP; Woods DJ
    Am J Health Syst Pharm; 1996 May; 53(10):1157-61. PubMed ID: 8734676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Pentravan
    Bourdon F; Lecoeur M; Leconte L; Ultré V; Kouach M; Odou P; Vaccher C; Foulon C
    Int J Pharm; 2016 Dec; 515(1-2):774-787. PubMed ID: 27826027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stability of Aprepitant Injectable Emulsion in Alternate Infusion Bags, in Refrigerated Storage, and Admixed with Dexamethasone and Palonosetron.
    Ottoboni T; Lerner L; Santhouse A
    Drug Des Devel Ther; 2021; 15():2519-2527. PubMed ID: 34163138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stability of extemporaneously prepared glycopyrrolate oral suspensions.
    Cober MP; Johnson CE; Sudekum D; Penprase K
    Am J Health Syst Pharm; 2011 May; 68(9):843-5. PubMed ID: 21515869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of buffer and antioxidant on stability of a mercaptopurine suspension.
    Aliabadi HM; Romanick M; Desai S; Lavasanifar A
    Am J Health Syst Pharm; 2008 Mar; 65(5):441-7. PubMed ID: 18281736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term stability of an infusion containing paracetamol, alizapride, ketorolac and tramadol in glass bottles at 5±3°C.
    Colsoul ML; Hecq JD; Soumoy L; Charles O; Goderniaux N; Bihin B; Jamart J; Galanti L
    Eur J Hosp Pharm; 2020 Mar; 27(e1):e74-e78. PubMed ID: 32296510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stability of itraconazole in an extemporaneously compounded oral liquid.
    Jacobson PA; Johnson CE; Walters JR
    Am J Health Syst Pharm; 1995 Jan; 52(2):189-91. PubMed ID: 12879547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stability study of oral pediatric idebenone suspensions.
    Schlatter J; Bourguignon E; Majoul E; Kabiche S; Balde IB; Cisternino S; Fontan JE
    Pharm Dev Technol; 2017 Mar; 22(2):296-299. PubMed ID: 27583702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4.
    Espana B; Joseph-Tornabène F; Jaquet C; Perrot S; Prouillac C
    Int J Pharm Compd; 2020; 24(4):327-336. PubMed ID: 32649306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stability of extemporaneously prepared oxandrolone oral suspensions.
    Johnson CE; Cober MP; Hawkins KA; Julian JD
    Am J Health Syst Pharm; 2011 Mar; 68(6):519-21. PubMed ID: 21378300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stability of extemporaneously prepared moxifloxacin oral suspensions.
    Hutchinson DJ; Johnson CE; Klein KC
    Am J Health Syst Pharm; 2009 Apr; 66(7):665-7. PubMed ID: 19299374
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stability of ursodiol in an extemporaneously compounded oral liquid.
    Johnson CE; Nesbitt J
    Am J Health Syst Pharm; 1995 Aug; 52(16):1798-1800. PubMed ID: 8528836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stability of extemporaneously prepared rufinamide oral suspensions.
    Hutchinson DJ; Liou Y; Best R; Zhao F
    Ann Pharmacother; 2010 Mar; 44(3):462-5. PubMed ID: 20150505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of an extemporaneous oral liquid formulation of oxandrolone and its stability evaluation.
    Garg A; Garg S; She RW
    Burns; 2011 Nov; 37(7):1150-3. PubMed ID: 21764219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stability of acetazolamide in suspension compounded from tablets.
    Alexander KS; Haribhakti RP; Parker GA
    Am J Hosp Pharm; 1991 Jun; 48(6):1241-4. PubMed ID: 1858804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stability of ursodiol 25 mg/mL in an extemporaneously prepared oral liquid.
    Mallett MS; Hagan RL; Peters DA
    Am J Health Syst Pharm; 1997 Jun; 54(12):1401-4. PubMed ID: 9194984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stability of Ribavirin for Inhalation Packaged in Syringes or Glass Vials when Stored Frozen, Refrigerated, and at Room Temperature.
    Larson B; Bushman LR; Casciano ML; Oldland AR; Kiser JJ; Kiser TH
    Int J Pharm Compd; 2016; 20(6):521-525. PubMed ID: 28339392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of aprepitant loaded orally disintegrating films for enhanced pharmacokinetic performance.
    Sharma R; Kamboj S; Singh G; Rana V
    Eur J Pharm Sci; 2016 Mar; 84():55-69. PubMed ID: 26780381
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relative bioavailability of an extemporaneously prepared aprepitant oral suspension in healthy adults.
    Patel P; Nathan PC; Walker SE; Zupanec S; Volpe J; Dupuis LL
    J Oncol Pharm Pract; 2019 Dec; 25(8):1907-1915. PubMed ID: 31694495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of terminal sterilization by irradiation on amber Type I and Type III glass containers containing veterinary oxytetracycline suspension.
    Wong J; Papadopoulos P; Rebbeck C; Schwabe S; Lischewski G; Melchert J; Kuu W; Agostinelli T; Smith T; Brame G; Lynn R; Hepler D
    PDA J Pharm Sci Technol; 2004; 58(1):6-14. PubMed ID: 15053050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.